IO Biotech, Inc.(NASDAQ:IOBT) 
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death...
Website: http://www.iobiotech.com
Founded: 2014
CEO / Founder: Mai-Britt Zocca
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 0.97
H 1.01
L 0.93
C 0.98
V 180,208
10EMA 0.98
20EMA 0.98
60EMA 0.98
120EMA 0.98
250EMA 0.98